GSK licensed an siRNA asset, SA-030, from Suzhou Siran Biotechnology in a deal with potential value up to $1 billion. The siRNA program has entered Phase I trials for cardiometabolic disease, expanding GSK’s participation in oligonucleotide therapeutics beyond its hepatitis and respiratory programs. The transaction includes an undisclosed up-front fee, development and regulatory milestones, and tiered royalties on global net sales. By taking exclusive worldwide rights, GSK positioned SA-030 as a candidate that could address cardiometabolic disease targets through gene-silencing. The agreement adds to a broader pattern of pharma partnering with China-based oligonucleotide and delivery specialists as clinical data and early safety profiles emerge. For SiranBio, the licensing provides funding and downstream development resources while potentially accelerating the transition from early clinical testing to larger trials.